Luengrojanakul P, Vareesangthip K, Chainuvati T, Murata K, Tsuda F, Tokita H, Okamoto H, Miyakawa Y, Mayumi M
Division of Gastroenterology, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
J Med Virol. 1994 Nov;44(3):287-92. doi: 10.1002/jmv.1890440313.
Hepatitis C virus (HCV) RNA and genotypes, as well as markers of hepatitis B virus infection, were surveyed in 171 patients with chronic liver disease, 276 patients with chronic renal failure, and 961 blood donors in Thailand. HCV RNA was detected in 30 (23%) of 128 patients with non-alcoholic chronic liver disease and hepatitis B surface antigen (HBsAg) in 60 (47%), and both HCV RNA and HBsAg in 3; the cause of liver disease was not established in 41 (32%) patients. HCV RNA was detected in 44 (20%) of 221 patients on maintenance hemodialysis or with kidney transplantation, but in none of 55 patients on peritoneal dialysis. Antibodies to synthetic HCV core peptides were detected in 39 (4.1%) of sera from 961 blood donors, and HCV RNA was detected in 8 (0.8%). Of the 90 HCV RNA samples from patients and donors, genotype V prevailed (46%) followed by II (22%), I (14%), III (3%), and VI (2%); genotypes were not classifiable into any of I-VI in the remaining 10%. There were six sera which contained HCV RNA, but were without antibody to HCV detectable by the second-generation enzyme immunoassay. HCV RNA titers were high in four patients with kidney transplantation, but low in one patient with chronic liver disease and one patient on maintenance hemodialysis. HCV RNA at high titer (> or = 10(4)/ml) was not classifiable in one patient. These results indicate HCV of novel genotypes in Thailand, seronegative HCV infection in patients with kidney transplantation, and a low risk of HCV infection in patients treated by peritoneal dialysis.
在泰国，对171例慢性肝病患者、276例慢性肾衰竭患者和961名献血者进行了丙型肝炎病毒（HCV）RNA和基因型以及乙型肝炎病毒感染标志物的检测。在128例非酒精性慢性肝病患者中，30例（23%）检测到HCV RNA，60例（47%）检测到乙型肝炎表面抗原（HBsAg），3例同时检测到HCV RNA和HBsAg；41例（32%）患者的肝病病因未明确。在221例维持性血液透析或肾移植患者中，44例（20%）检测到HCV RNA，但55例腹膜透析患者均未检测到。在961名献血者的血清中，39例（4.1%）检测到针对合成HCV核心肽的抗体，8例（0.8%）检测到HCV RNA。在来自患者和献血者的90份HCV RNA样本中，V型占主导（46%），其次是II型（22%）、I型（14%）、III型（3%）和VI型（2%）；其余10%的样本无法归类为I - VI型中的任何一种。有6份血清含有HCV RNA，但第二代酶免疫测定法检测不到抗HCV抗体。4例肾移植患者的HCV RNA滴度较高，但1例慢性肝病患者和1例维持性血液透析患者的滴度较低。1例患者的高滴度（≥10⁴/ml）HCV RNA无法归类。这些结果表明泰国存在新型基因型的HCV、肾移植患者中存在血清学阴性的HCV感染以及腹膜透析患者中HCV感染风险较低。
